VERU

VERU

USD

Veru Inc. Common Stock

$2.650+0.070 (2.713%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$2.580

Máximo

$2.650

Mínimo

$2.580

Volume

0.18M

Fundamentos da empresa

Capitalização de mercado

42.5M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.18M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $2.42Atual $2.650Máximo $14.2

Relatório de análise de IA

Última atualização: 10/11/2025
Gerado por IAFonte de dados: Yahoo Finance, Bloomberg, SEC

VERU Stock Analysis: Veru Inc. Navigates Volatility Amid Fundamental Challenges

Market Snapshot

Current Price: $2.61 (as of 2025-11-10) 52-Week Range: $2.42 - $14.20 Market Cap: $41.89M | P/E Ratio: -9.00 Recent Volatility: Sharp decline from $4.43 (Oct 20) to $2.61, with erratic volume patterns


Recent Performance: Turbulent Descent

Veru’s stock has been in a clear downtrend since mid-October, shedding 41% from its October peak. Key observations:

  • Public Offering Impact: The $25M offering on Oct 30 likely triggered selling pressure, with shares dropping 12% the following day.
  • Volume Anomalies: Unusually high trading volume on Oct 30 ($765,700) and Nov 3 ($489,500) suggests panic selling or institutional exits.
  • Support Zone: Recent closes near $2.52-$2.58 align with its 52-week low, indicating this range may act as temporary support.

Technical Signals: Mixed Messages

  • Bullish DMI: +DI (15.4) > -DI (14.1) with ADX at 19.0 implies a weak uptrend could form if buyers step in.
  • Volume Surge: 1.9x average volume on Nov 10 hints at renewed interest, but this could reflect short-term positioning rather than sustainable demand.
  • MACD Death Cross: Bearish momentum confirmed as MACD (0.0119) fell below signal line (0.0162) despite AI’s upward projections.

Fundamentals: Value Trap or Hidden Potential?

  • Contradictory Valuation: While the P/E (-9.00) appears broken due to negative earnings, the recommendation claims it’s “0.4x industry average” (likely referencing EBITDA multiples or forward estimates). Proceed with skepticism.
  • **High-Risk

Notícias relacionadas

GlobeNewswire

Veru to Present Two Abstracts at ObesityWeek 2025

MIAMI, FL, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Ver mais
Veru to Present Two Abstracts at ObesityWeek 2025
GlobeNewswire

Veru Announces Pricing of $25 Million Public Offering

MIAMI, FL, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory

Ver mais
Veru Announces Pricing of $25 Million Public Offering

Previsão de IABeta

Recomendação de IA

Altista

Atualizado em: 10/11/2025, 14:42

BaixistaNeutroAltista

58.4% Confiança

Risco e negociação

Nível de risco3/5
Risco médio
Adequado para
Valor
Guia de negociação

Ponto de entrada

$2.52

Tomar lucro

$2.61

Parar perda

$2.30

Fatores-chave

PDI 15.4 está acima do MDI 14.1 com ADX 19.0, sugerindo tendência de alta
O volume de negociação é 1.9x a média (3,174), indicando aumento da participação de mercado
MACD 0.0119 está abaixo da linha de sinal 0.0162, indicando um crossover de baixa

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.